Giulia Lupparelli

Predicting the probability of Gaucher disease in subjects with splenomegaly and thrombocytopenia

D. Consonni, A. Patriarca, M. Filocamo, 2021, Scientific Reports.

Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.

B. Barlogie, M. Dimopoulos, P. Sonneveld, 2014, The Lancet. Oncology.

Second Primary Malignancies in Newly Diagnosed Multiple Myeloma Patients Treated with Lenalidomide: Analysis of Pooled Data in 2459 Patients

P. Sonneveld, M. Boccadoro, D. Rossi, 2011 .

Secondary malignancies in elderly myeloma patients

M. Dimopoulos, P. Sonneveld, R. Hájek, 2011 .

Does Low-Molecular-Weight Heparin Influence the Antimyeloma Effects of Thalidomide? A Retrospective Analysis of Data from the GIMEMA, Nordic and Turkish Myeloma Study Groups

G. Juliusson, S. Bringhen, A. Waage, 2015, Acta Haematologica.

Second primary malignancies (SPM) in newly diagnosed myeloma (MM) patients treated with lenalidomide (Len): Meta-analysis of 6,383 individual patient data (IPD).

B. Barlogie, M. Dimopoulos, P. Sonneveld, 2013 .